Archive ready

新型コロナウイルス治療薬の特例承認について｜厚生労働省

https://www.mhlw.go.jp/stf/newpage_23815.html

April 10, 2026 at 03:02 AM JST•The archive page, viewer, and downloads use this saved version.

April 10, 2026 at 03:02 AM JST·www.mhlw.go.jp

The evidence pack includes HTML, screenshots, summaries, and metadata. It can be downloaded on Pro.

Saved page

新型コロナウイルス治療薬の特例承認について｜厚生労働省

Open the archived HTML with saved-time metadata attached.

Original URLhttps://www.mhlw.go.jp/stf/newpage_23815.html

StartedApril 10, 2026 at 03:02 AM JST

This HTML has CSS and images embedded, so it can still be opened even if the original page disappears.

About this pageAI generated

This page announces the exceptional approval of a COVID-19 treatment drug by Japan's Ministry of Health, Labour and Welfare on February 10, 2022. Pfizer's "Paxlovid Pack" (generic name: nirmatrelvir and ritonavir) received special approval under Article 14-3 of the Pharmaceutical Affairs Law. The application was submitted on January 14, 2022, for treating SARS-CoV-2 infections. Additional details are provided in the attached press release and statement from the Minister of Health, Labour and Welfare.

Screenshot

The full page can be captured up to 15,000px in height so you can review the complete page layout when needed.